Patients with neovascular age-related macular degeneration experienced visual benefits and anatomic improvements with extended dosing intervals of IBI302, according to a press release from Innovent Biologics.
In a second phase 2 clinical trial of intravitreal IBI302 (efdamrofusp alfa), a recombinant fully human bispecific fusion protein, 132 Chinese patients were randomly assigned to receive IBI302 6.4 mg, IBI302 8 mg or aflibercept 2 mg. Dosing intervals for IBI302 were adjusted depending on the response to the loading therapy.
The primary endpoint of the 52-week study was the change in best